Uveal melanoma patient attitudes towards prognostic testing using gene expression profiling.

IF 1 Q4 ONCOLOGY Melanoma Management Pub Date : 2022-09-16 eCollection Date: 2022-09-01 DOI:10.2217/mmt-2022-0003

Basil K Williams, Jennifer J Siegel, Katherina M Alsina, Lauren Johnston, Amanda Sisco, Kyleigh LiPira, Sara M Selig, Peter G Hovland

{"title":"Uveal melanoma patient attitudes towards prognostic testing using gene expression profiling.","authors":"Basil K Williams, Jennifer J Siegel, Katherina M Alsina, Lauren Johnston, Amanda Sisco, Kyleigh LiPira, Sara M Selig, Peter G Hovland","doi":"10.2217/mmt-2022-0003","DOIUrl":null,"url":null,"abstract":"Aim: This study explored uveal melanoma patient experiences and regret following molecular prognostic testing using a 15-gene expression profile (GEP) test.Materials & methods: A retrospective, cross-sectional survey study was conducted through an online questionnaire capturing patient-reported experiences with prognostic biopsy/molecular testing.Results: Of 177 respondents, 159 (90%) wanted prognostic information at diagnosis. Most 15-GEP-tested patients who shared their results (99%) reported gaining value from testing, as did patients tested with other methods. Patients who received prognostic testing experienced lower decision regret than those who opted out. Decision regret did not differ based on GEP class.Conclusion: Most uveal melanoma patients desire prognostic testing and gain value from the GEP, independent of a high- or low-risk result.","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2022-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c8/d2/mmt-09-62.PMC9490505.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Melanoma Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/mmt-2022-0003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/9/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Aim: This study explored uveal melanoma patient experiences and regret following molecular prognostic testing using a 15-gene expression profile (GEP) test.

Materials & methods: A retrospective, cross-sectional survey study was conducted through an online questionnaire capturing patient-reported experiences with prognostic biopsy/molecular testing.

Results: Of 177 respondents, 159 (90%) wanted prognostic information at diagnosis. Most 15-GEP-tested patients who shared their results (99%) reported gaining value from testing, as did patients tested with other methods. Patients who received prognostic testing experienced lower decision regret than those who opted out. Decision regret did not differ based on GEP class.

Conclusion: Most uveal melanoma patients desire prognostic testing and gain value from the GEP, independent of a high- or low-risk result.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

葡萄膜黑色素瘤患者对使用基因表达谱进行预后检测的态度。

目的:本研究探讨葡萄膜黑色素瘤患者使用15基因表达谱(GEP)测试进行分子预后检测后的经历和后悔。材料和方法:通过在线问卷收集患者报告的预后活检/分子检测经验，进行回顾性横断面调查研究。结果:在177名应答者中，159名(90%)在诊断时需要预后信息。大多数接受15- gep测试的患者(99%)报告说他们从测试中获得了价值，接受其他方法测试的患者也是如此。接受预后检测的患者比不接受预后检测的患者有更低的决策后悔。决策后悔没有因GEP等级而异。结论:大多数葡萄膜黑色素瘤患者希望进行预后检测，并从GEP中获得价值，而不依赖于高风险或低风险的结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Melanoma Management ONCOLOGY-

CiteScore

5.10

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Skin cancer is on the rise. According to the World Health Organization, 132,000 melanoma skin cancers occur globally each year. While early-stage melanoma is usually relatively easy to treat, once disease spreads prognosis worsens considerably. Therefore, research into combating advanced-stage melanoma is a high priority. New and emerging therapies, such as monoclonal antibodies, B-RAF and KIT inhibitors, antiangiogenic agents and novel chemotherapy approaches hold promise for prolonging survival, but the search for a cure is ongoing. Melanoma Management publishes high-quality peer-reviewed articles on all aspects of melanoma, from prevention to diagnosis and from treatment of early-stage disease to late-stage melanoma and metastasis. The journal presents the latest research findings in melanoma research and treatment, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. Key topics covered include: Risk factors, prevention and sun safety education Diagnosis, staging and grading Surgical excision of melanoma lesions Sentinel lymph node biopsy Biological therapies, including immunotherapy and vaccination Novel chemotherapy options Treatment of metastasis Prevention of recurrence Patient care and quality of life.